Rozanolixizumab: A New Therapy in the Treatment of Myasthenia Gravis

CONCLUSION/RELEVANCE: The approval of rozanolixizumab represents an advancement in therapy for generalized myasthenia gravis. The provision of individualized, targeted, and well-tolerated treatment is valuable for the patients whose myasthenia gravis is not well controlled and who are seeking a medication with a rapid onset of action to improve their symptoms and overall quality of life.PMID:38533739 | DOI:10.1177/10600280241239048
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Source Type: research